Smith Anderson Advises Vogenx on $93.4 Million Initial Public Offering

Smith Anderson client Vogenx Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, recently completed its initial public offering and began trading on the Nasdaq Capital Market under the ticker symbol “VOGX.”

Vogenx sold an aggregate of 7,187,500 million shares of common stock at a public offering price of $13 per share in the initial public offering, including 937,500 shares sold pursuant to the full exercise by the underwriter of its over-allotment option. The offering generated approximately $93.4 million in gross proceeds before underwriting discounts, commissions, and offering expenses. The transaction represents an important milestone for Vogenx as it continues advancing novel therapeutics for patients with serious metabolic diseases, including post-bariatric hypoglycemia and gastroparesis.

“This offering is an important step for Vogenx as we continue advancing our pipeline and working to develop new treatment options for patients with serious metabolic diseases,” said James Green, CEO of Vogenx. “We are grateful to the Smith Anderson team for their guidance and commitment throughout the IPO process and for helping us reach this next stage in our company’s growth.”

Smith Anderson’s Public Companies group represented Vogenx throughout the IPO process, helping the company navigate the path to the public markets. Led by Heyward Armstrong, Tyler Cook, and Benji Jones, the multidisciplinary team advising Vogenx included Amy Batten, Alex Bowling, Chris Capel, Kevin Ceglowski, Brian Ferrell, Tory Hartmann, Jamie Hinkle, John Jo, Megan Lambert, Jason Martinez, Olivia Meade, Bill Nelson, Alex Simpson, Meredith Whatley, and Nick Zanzot.

Tyler Cook, Benji Jones, and Olivia Meade joined Vogenx at Nasdaq to mark the company’s debut on the public markets and participate in the bell-ringing ceremony.

Smith Anderson’s Public Companies group advises companies at every stage of the public company lifecycle, from private companies considering an IPO to established public companies navigating securities compliance, capital raising, corporate governance, stock exchange requirements, and strategic transactions. The team routinely advises on public and private debt and equity offerings, SEC reporting and disclosure, exchange listings and compliance, investor relations, and corporate governance matters.